Procedural steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 February 2004 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The changes introduced in the revision 1 of this EPAR are editorial amendments to Part III, 
section 4: Overview of part IV of the dossier: clinical aspects. 
The MAH submitted on 26 March 1997 an application for a Type II variation, in order to apply 
for  the  use  of  NovoSeven  also  outside  of  specialized  centres,  pursuant  to  Article  6  of 
Commission Regulation (EC) No 542/95 of 10 March 1995. The procedure started on 18 April 
1997,  supplementary  information  was  supplied  by  the  MAH  on  1  July  1997  and  a  positive 
opinion  was  adopted  by  the  CPMP  on  23  July  1997.  The  European  Commission  granted  a 
Commission decision on 4 December 1997. 
The MAH submitted on 23 July 1997, three applications for three Type I variations No 12 of 
Annex I, (type II procedure applicable) in order to apply for a change in the manufacture of the 
bulk  product,  pursuant  to  Article  4  of  Commission  Regulation  (EC)  No  542/95  of  10  March 
1995 as amended. The procedures started on 25 July 1997 and a positive opinion was adopted 
by the CPMP on 24 September 1997. 
The MAH submitted on 16 April 1998, an application for a Type I variation No 12 of Annex I, 
(type  II  procedure  applicable)  in  order  to  remove  the  bovine  derived  Primatone  RL  from  the 
cultivation process in order to minimise the use of animal derived material, pursuant to Article 4 
of  Commission  Regulation  (EC)  No  542/95  of  10  March  1995  as  amended.  The  procedure 
started on 24 April 1998 and a positive opinion was adopted by the CPMP on 24 June 1998. 
The MAH submitted on 16 April 1998 an application for a Type II variation, in order to apply 
for an additional needle for injection, pursuant to Article 6 of Commission Regulation (EC) No 
542/95 of 10 March 1995 as amended. The procedure started on 24 April 1998, supplementary 
information was supplied by the MAH on 10 July 1998 and a positive opinion was adopted by 
the CPMP on 23 July 1998. The European Commission granted a Commission decision on 19 
November 1998. 
The MAH submitted on 6 April 1998, an application for a Notification of a Type I variation No 
20 of Annex I, in order to change the shelf-life of the finished product, pursuant to Article 4 of 
Commission Regulation (EC) No 542/95 of 10 March 1995 as amended. The procedure started 
on 16 April 1998 and a positive opinion was adopted by the CPMP on 15 May 1998. 
The  MAH  submitted  on  30  October  1998  an  application  for  a  Type  II  variation,  in  order  to 
apply for the extension of the storage period/shelf life of bulk product, pursuant to Article 6 of 
Commission Regulation (EC) No 542/95 of 10 March 1995 as amended. The procedure started 
on 20 November 1998 and a positive opinion was adopted by the CPMP on 27 January 1999. 
The  MAH  submitted  on  30  October  1998  an  application  for  a  Type  II  variation,  in  order  to 
apply  for  changes  in  the  bulk  product  specification,  pursuant  to  Article  6  of  Commission 
Regulation  (EC)  No  542/95  of  10  March  1995  as  amended.  The  procedure  started  on  20 
November 1998 and a positive opinion was adopted by the CPMP on 27 January 1999. 
The  MAH  submitted  on  30  October  1998  an  application  for  a  Type  II  variation,  in  order  to 
apply  for  the  replacement  of  the  test  for  pyrogens,  pursuant  to  Article  6  of  Commission 
Regulation  (EC)  No  542/95  of  10  March  1995  as  amended.  The  procedure  started  on  20 
November 1998 and a positive opinion was adopted by the CPMP on 27 January 1999. 
The MAH submitted on 30 October 1998, an application for a Type I variation No 12 of Annex 
I,  (type  II  procedure  applicable)  in  order  to  apply  for  minor  changes  to  the  manufacturing 
1/2 
 EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
process  related  to  the  fermentation  and  purification  processes,  pursuant  to  Article  4  of 
Commission Regulation (EC) No 542/95 of 10 March 1995 as amended. The procedure started 
on 18 December 1998 and a positive opinion was adopted by the CPMP on 23 February 1999. 
The MAH submitted on 30 October 1998, an application for a Type I variation No 11 of Annex 
I,  (type  II  procedure  applicable)  for  the  addition  of  an  alternative  manufacturer  of  the  raw 
material, pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 10 March 1995 as 
amended. The procedure started on 18 December 1998 and a positive opinion was adopted by 
the CPMP on 23 February 1999. 
The MAH submitted on 19 May 1999 an application for a Type II variation at the request of the 
CPMP  following  the  the  evaluation  of  the  4th  and  5th  PSUR,  in  order  to  modify  the  SPC  and 
Package Leaflet, pursuant to Article 6 of Commission Regulation (EC) No 542/95 of 10 March 
1995  as  amended.  The  procedure  started  on  21  May  1999,  supplementary  information  was 
supplied by the MAH on 30 June 1999 and a positive opinion was adopted by the CPMP on 28 
July 1999. The European Commission granted a Commission decision on 8 December 1999. 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
Quality changes 
Replacement of an excipient with a comparable excipient 
Renewal 
Update of summary of product characteristics and package leaflet 
Changes to comply with supplements to pharmacopoeias 
Minor change of manufacturing process of the active substance 
Minor change of manufacturing process of the active substance 
Synthesis or recovery of non-pharmacopoeial excipients in the 
medicinal products 
Change in test procedure of active substance and Change in test 
procedures of the medicinal product 
Change in the batch size of finished product 
Minor changes in manufacture of the medicinal product 
Change(s) to shelf-life or storage conditions 
Extension of Indication 
Extension of Indication 
Update of Summary of Product Characteristics and Package Leaflet 
Update of Summary of Product Characteristics and Package Leaflet 
Change in test procedure of active substance 
II/15 
I/16 
R/17 
II/18 
I/19 
I/20 
I/21 
I/22 
I/23 
I/24 
I/25 
II/27 
II/28 
II/29 
II/30 
II/31 
I/32 
II 
I 
R 
II 
I 
I 
I 
I 
I 
I 
I 
II 
II 
II 
II 
II 
I 
Commission 
Decision 
Issued/amen
ded on 
28.11.00 
12.10.00 
3.05.01 
20.06.01 
06.04.01 
29.04.02 
29.04.02 
15.07.02 
19.10.00 
15.09.00 
25/01.01 
01.03.01 
13.03.01 
25.04.02 
25.04.02 
15.07.02 
21.11.02 
09.12.02 
20.02.03 
20.02.03 
24.07.03 
22.10.03 
22.10.03 
25.09.03 
25.09.03 
22.08.03 
10.03.03 
10.03.03 
08.10.03 
27.01.04 
27.01.04 
27.01.04 
27.01.04 
22.09.03 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
2/2 
 EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
